ABBV +0.71% NVDA -1.43% Explore stocks on Coinbase Trading disclosure Trading disclosure The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
AbbVie (NYSE: ABBV), which accounts for 6.2% of my portfolio, is one of my favorite long-term dividend stocks. The pharmaceutical giant has raised its dividend annually for 53 consecutive years, making it a Dividend King that has increased its payout for at least 50 years.
I'm sitting on an unrealized gain of nearly 200% on my original position in AbbVie, which I started in early 2020, and I've consistently reinvested my dividends. Its forward yield of 2.4% might seem low compared to the 10-Year Treasury's 5.1% yield. Still, its low forward price-to-earnings ratio of 16 and its massive portfolio of billion-dollar drugs (including the blockbusters Skyrizi and Rinvoq) should limit its downside potential in this choppy market.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
To earn $5,000 in annual dividends from AbbVie, you would need to own 723 shares for about $206,358 as of this writing. That might not seem like a great deal, especially when the same investment in Pfizer (NYSE: PFE) would generate nearly $12,000 in annual dividends.
But over the past three years, AbbVie's stock rallied 93% as it overcame its loss of U.S. exclusivity for Humira (its blockbuster autoimmune drug) and expanded its new drugs to offset that pressure. Pfizer's stock sank 8% as its sales of COVID-19 vaccines evaporated and its other major drugs faced patent cliffs. Therefore, AbbVie could still be a solid investment for long-term income investors, even though its yield seems unimpressive.
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AbbVie wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $391,581!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,334,780!*
Now, it's worth noting Stock Advisor's total average return is 936% — a market-crushing outperformance compared to 213% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of October 16, 2026.
Leo Sun has positions in AbbVie and Pfizer. The Motley Fool has positions in and recommends AbbVie and Pfizer. The Motley Fool has a disclosure policy.
Here's How Many Shares of AbbVie You'd Need for $5,000 in Yearly Dividends was originally published by The Motley Fool
